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Abstract
In newborn the innate immune system provides essential protection during primary infections before the generation of an
appropriate adaptive immune response that is initially not fully operative. Innate immune response is evoked and
perpetuated by molecules derived from microorganisms or by the damage/death of host cells. These are collectively known
as damage-associated molecular-pattern (DAMP) molecules. High-mobility group box 1 protein (HMGB1) or amphoterin,
which previously was considered to be only a nuclear factor, has been recently identified as a DAMP molecule. When it is
actively secreted by inflammatory cells or passively released from necrotic cells, HMGB1 mediates the response to infection,
injury and inflammation, inducing dendritic cells maturation and T helper-1-cell responses. To characterize the role of
HMGB1 in the innate and immature defense mechanisms in newborns, human cord blood (CB) mononuclear cells, in
comparison to adult peripheral blood (PB) mononuclear cells, have been analyzed for its expression. By flow cytometry and
western blot analysis, we observed that in CB and PB cells: i) HMGB1 is expressed on cell surface membranes of myeloid
dendritic cell precursors, mostly, and lymphocytes (gamma/delta and CD4
+ T cells) to a lesser extent; ii) different pro-
inflammatory stimuli or molecules that mimic infection increased cell surface expression of HMGB1 as well as its secretion
into extracellular environment; iii) the treatment with synthetic molecules such as aminobisphosphonates (ABs), identified
to be cd T cell antigens, triggered up-regulation of HMGB1 expression on mononuclear cells, as well cd T lymphocytes,
inducing its secretion. The modulation of its secretion and the HMGB1-mediated migration of monocytes indicated HMGB1
as regulator of immune response in an immature system, like CB, through engagement of cd T lymphocytes and myeloid
dendritic cell precursors, essential components of innate immunity. In addition, the increased HMGB1 expression/secretion
triggered by ABs, previously characterized for their immuno-modulating and immune-adjuvant capabilities, indicated that
immunomodulation might represent a new therapeutical approach for neonatal and adult pathologies.
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Introduction
The neonatal immune system is generally considered to be
immature and less functional compared to adult counterpart. This
immaturity is thought to account for the failure of the newborn to
mount robust and protective response against several pathogens,
resulting in increased mortality [1–4]. The impairment of the
newborn immune system may result from the combined effects
of a number of factors including: immaturity of its cellular
components; lack of previous exposure to antigens; intra-uterine
exposureto unique hormonal and cytokine environment whichmay
support Th2 subset development; low proliferation capacity of T
lymphocytes and its impaired Th1 cytokine production. Therefore,
at the onset of microbial infections, before the generation of an
appropriate adaptive (antibody or T cell mediated) immune
response, the most important line of defense is innate immunity,
where cd T lymphocytes together with dendritic cells (DCs),
macrophages/monocytes and NK cells are the essential compo-
nents. Innate immunity triggers proinflammatory reactions and is
involved in the initial clearance of pathogens.
During the last decade it has been observed that the innate
immune response also orchestrates the subsequent adaptive
immune response through cytokines and chemokines released by
macrophages, DCs and Langerhans cells that are differently
activated by the initial innate response. Unlike adaptive immunity,
innate immunity is programmed to recognize series of molecular
patterns present at the infected lesion: (i) the patterns that are
presented by microorganisms [pathogen-associated molecular
patterns (PAMPs)], and (ii) the patterns of host intracellular
molecules secreted by dying host cells into the extracellular spaces
upon microorganism-induced damage [damage-associated molec-
ular patterns (DAMPs)] [5–8]. Consequently, the co-existence of
PAMPs and DAMPs signals after invasion by pathogenic
microorganisms are closely associated to tissue damage.
The list of DAMPs candidate molecules is getting longer and
includes high mobility group box 1 (HMGB1), heat shock proteins,
interleukin-1a (IL-1a), defensins, annexins, and S100 [9–13].
HMGB1, or amphoterin, previously has been reported to be only
a nuclear factor able to enhance transcription. More recently,
HMGB1 has been demonstrated to be a crucial cytokine that
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HMGB1 is a 30 kD nuclear protein of 215 amino acids. It includes
two DNA-binding domains: the A box and the B box, and a
negatively charged C-terminal tail. Truncation of HMGB1
indicates that the recombinant A box (1–89) acts as a specific
antagonist, whereas the cytokine activity of HMGB1 is determined
by the recombinant B box (90–176) [14]. The first 20 amino acids
of the recombinant B box represent the minimal peptide
maintaining cytokine activity.
HMGB1recruitsinflammatorycellsand activatesinnateimmune
cells. Further, after release from necrotic cells or its secretion by
activated macrophages, it regulates adaptive immunity [13,15–17].
Moreover, HMGB1 supports the maturation and migration of
antigen-presenting cells, in particular DCs, to secondary lymphoid
organs where these cells play a central role in the activation of naive
T cells,inthepromotionandinductionofTh1responses,andclonal
expansion of antigen-specific T cells, the process at the basis of the
adaptive immune response [18,19]. Recently, Kalyan S [20] has
reported that peripheral cd T lymphocytes, previously activated by
nonpeptidic antigen isopentylpyrophosphate (IPP), induced the
upregulation of CD40 on monocytes and the local release of
HMGB1, indicating cd T cells as immune modulators of stress
stimuli and Th1 polarization together with HMGB1. In immune
response, cd T cells represent the first line of defense and are
considered to be the border between innate and adaptive immune
response. Interestingly, aminobisphosphonates (ABs) which are
synthetic compounds commonly used to treat bone disease and
hypercalcemiain patients withmultiple myeloma, breast or prostate
cancer, have been identified also as antigens for cd T cells,
indicating these molecules as immunomodulating factors [21–26].
The expression of HMGB1 and its role in immune response has
been demonstrated successfully in adult peripheral blood (PB). Only
recently, Buhimashi CS et al [27] observed that HMGB1, together
with soluble receptor for advanced glycation end-products (sRAGE)
and S100, may be important mediators of cellular injury in fetuses
and crucial factor in preterm birth induced inflammation.
Therefore, due to the importance in understanding immature and
innate immune profiles in newborn, we have characterized the
expression and modulation of HMGB1 in human cord blood (CB)
mononuclear cells.
Results
HMGB1 is expressed on cell-surface of human cord blood
cells
Since HMGB1 is present in serum of human cord blood,
indicating it as possible mediator of inflammation in fetuses [27],
by FACS analysis we first evaluated the intracellular expression of
HMGB1 in human CB and PB derived cells in comparison to
HeLa cells, known to express HMGB1. Due to the fact that
HMGB1 is a nuclear factor, the totality of CB and PB per-
meabilized cells showed the presence of intracellular HMGB1
expression at a comparable frequency of HeLa cells (Fig. 1A). In
addition, we evaluated cell surface expression of HMGB1 in
absence of permeabilization, ever since any data was reported on
its expression in CB cells. To this end, mononuclear cells isolated
from human CB were cultured in complete growth medium and
the HMGB1 expressing cells were determined 48 h after isolation.
Flow cytometry analysis indicated that 13%64 (n=8) CB
mononuclear cells expressed HMGB1 on their surface whilst in
PB cells HMGB1 was present on 6.5%61.8 of cells (n=8)
(Fig. 1A). Interestingly, CB cells presented a significantly higher
constitutive HMGB1 expression than PB (p=0.02). Fig. 1B shows
the overlay of fluorescence histogram plots in one representative
CB respect to PB, indicating the higher percentage of HMGB1
expressing cells (8.5% in CB versus 5% in PB). In HeLa cells,
HMGB1 is expressed by a mean of 7.6%61 cells.
HMGB1 is expressed mainly on myeloid DC precursors
After 48 h of cell culture in complete growth medium, by multi
color flow cytometric analysis we evaluated the cell distribution of
HMGB1 expression on different cell subsets of CB and PB. As
shown in Fig. 2A, in CB cells about 90% of HMGB1 is expressed
on myeloid DC precursors identified in two subsets with
CD14
+CD11c
+ and CD14
2D11c
+ phenotype [28]. Only a small
portion of HMGB1 (11%68) positive cells is represented by CD3
+
subset. These results were further corroborated by data achieved
in PB, showing a pattern of cell surface HMGB1 expression
comparable to CB (Fig. 2A). In Fig. 2B, a representative dual-color
FACS plot analysis indicated that the large part of CB CD11c
+
cells were positive for HMGB1. On the contrary, only a small
fraction of CD3
+ expressed HMGB1. Similar data were obtained
Figure 1. HMGB1 is expressed in human cord blood cells.
Mononuclear cells isolated from human cord (CB) and peripheral blood
(PB) have been cultured in complete growth medium in absence of
external stimuli. (A) The intracellular and surface expression of HMGB1
has been determined 48 h after isolation by flow cytometry analysis in
permeabilzed and non-permeabilized cells, respectively. HeLa cells
represent the reference cell line known to be HMGB1 positive. Values
(mean 6 SD of eight experiments from different donors) are expressed
as percentage of cells labeled with anti-HMGB1 antibody. (B) The
fluorescence histogram plot derived from FACS analysis shows the
HMGB1 expression profile of CB cells (solid line) and PB cells (dotted
line). The percentage of HMGB1 positive cells is indicated in graph. The
histogram plot is representative of eight different experiments.
doi:10.1371/journal.pone.0023766.g001
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subsets of HMGB1 positive lymphocytes, the CD3
+ HMGB1
+ cell
population has been further characterized by flow cytometry using
monoclonal antibodies for CD4, CD8 and TCR gammadelta
(Vd2). As reported in Fig. 2C, cell surface expression of HMGB1
was confined primarily in Vd2 T cells both in CB and PB. Also
CD4
+ T-cells resulted positive for HMGB1, whilst CD8
+ lym-
phocytes did not present any expression of HMGB1.
The previous reported data show the expression of HMGB1 on
a population of differentiated cells having a high forward scatter,
corresponding potentially to myeloid DC precursors. In order to
further support them, we analyzed CB and PB cells after 14 days
of cell culture because two different cell populations were
identified: adherent and non-adherent cells. By FACS analysis,
we observed that CB adherent cells expressed a significantly higher
levels of HMGB1 than non-adherent (14%65 versus 7%63i n
non-adherent cells, P=0.003) (Fig. 3A–B). On the contrary, in PB
the two cell populations displayed a similar levels of HMGB1 cell
surface expression (P=0.14). However, although not statistically
significant, the PB adherent cells showed a trend toward higher
HMGB1 expression compared to non-adherent cells. The
different levels of HMGB1 expression between CB and PB cells
observed at 48 h, has been found also after 14 days of culture in
the adherent cell subset.
In this context, CB adherent cells shows a shift in the fluorescence
curve to the right, indicating a greater expression of HMGB1 in
adherent than non-adherent cells (Fig. 3B). On the contrary, in PB
cells the level of fluorescence appears only slight different in
adherent or non adherent subpopulations (Fig. 3B). Moreover,
further characterization by FACS analysis indicated that HMGB1-
positive adherent cells were CD14
+CD11c
+ and CD14
2D11c
+
cells, confirming the results obtained at 48 h (Fig. S1).
Figure 2. Distribution of HMGB1 cell surface expression: myeloid DC precursors are main cell subset. At 48 h after isolation of
mononuclear cells from CB and PB, multi-color flow cytometric analysis has been performed to evaluate surface-expressed HMGB1 and expression of
cellular differentiation markers. (A) Two main subsets were identified to be HMGB1 positive in CB and PB: CD3
+, lymphocytes; CD14
+CD11c
+ and
CD14
2 CD11c
+, myeloid DC precursors. Values (mean 6 SD of five experiments from different donors) are expressed as percentage of HMGB1
positive cell subset among the totality of HMGB1 expressing cells. (B) Representative histogram plots derived from two-color FACS analysis show the
percentage, indicated on the right of each plot (upper right panel), of HMGB1
+ CD3
+ (left plot), HMGB1
+ CD14
+ (middle plot) and HMGB1
+ CD11c
+
(right plot) in CB cells. Histograms plots are representative of five different experiments. (C) In order to characterize the different T lymphocyte
subsets, CB and PB cells have been gated for lymphocytes and multi-color stained with HMGB1, CD3 and gammadelta (Vd2) or CD8 or CD4
antibodies. The values are the mean 6 SD of five experiments from different donors.
doi:10.1371/journal.pone.0023766.g002
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secretion
In peripheral blood, HMGB1 has been recently demonstrated
to be a cytokine secreted by activated immune cells and mediate
the response to infection, injury and inflammation. Therefore, we
investigated whether various activation signals, such as proin-
flammatory stimuli (TNF-a or IL-2 or IL-15), or signals that mimic
infection (LPS, SEB or PMA), influence the cell surface expression
and active secretion of HMGB1 by human cord blood cells. As
shown in Fig. 4A, flow cytometry analysis indicated that cell
surface expression of HMGB1 was up-regulated by all stimuli.
TNF-a increased HMGB1 levels by 2.5-folds in CB and 1.7-folds
in PB cells over control at 14 days after treatment. At the same
time point, up to approximately 5-folds increase in HMGB1
expression was observed in CB cells treated with IL-15 in contrast
to PB cells in which up-regulation reached only 2-folds over
control. In addition, IL-2 treatment showed a similar stimulation
of HMGB1 expression in CB and PB cells. Similar trend in
HMGB1 up-regulation has been observed after 48 h of treatment
with stimuli mimicking infection. SEB and PMA determined a
similar induction of HMGB1 expression both in cord blood and
peripheral blood cells (2-folds), whilst LPS showed a higher
increase of protein expression in CB (2-folds) than PB cells (0.8-
folds). To determine whether the triggered expression of HMGB1
on cell membrane was associated to its secretion, western blot
analysis was performed on the culture medium of CB and PB cells.
All different stimuli induced secretion of HMGB1 from CB and
PB cells at 48 h and 14 day after treatment (Fig. 4B), while no
detectable amounts of HMGB1 has been found in untreated cell
medium. Quantitative evaluation of HMGB1 band intensity
revealed that IL-2, IL-15 and LPS determined a greater secretion
of protein in CB than PB cells (Fig. 4B). On the other hand, TNF-
a, SEB and PMA determined the secretion of similar amount of
HMGB1 in the two cell types (Fig. 4B). Interestingly, the levels of
cell surface expression and secretion of HMGB1 resulted strictly
correlated. Moreover, the constitutive and the inducible expres-
sion level observed, presented a similar trend toward higher
prevalence in CB cells.
To determine whether the modulation of HMGB1 expression in
CB cells was associated to different intracellular localization of
HMGB1, LPS treated CB cells were co-stained with anti-HMGB1
(stained in green) and membrane-specific PKH26 red fluorescent
dye. Confocal immunofluorescence microscopy revealed that in
resting CB cells HMGB1 presented heterogeneous labeling
pattern, and was localized to the nucleus/cytoplasm, as well as
under the apical membrane and faintly on cell surface (Fig. 4C).
After forty-eight hours of LPS stimulation, HMGB1 appeared to
move from the nucleus/cytoplasm, which is still partly positive, to
the periphery of the cells and precisely around its external
perimeter, as indicated by the colocalization with membrane-
specific PKH26, well evident in the cell with peripheral section
(Fig. 4C). This change in surface expressed HMGB1 was
completely confirmed by FACS analysis above reported (Fig. 4A).
The constitutive and inducible expression of HMGB1 is
regulated via non-classical secretory pathway
Recently, Gardella et al [29], showed that IL-1b and HMGB1
were secreted by monocytes via non-classical secretory pathway
and HMGB1 secretion was reduced by Atp Binding Cassette
trasporter (ABC-1) inhibitors. To investigate the effect of ABC-1
inhibitor on HMGB1 expression and secretion in CB and PB cells,
mononuclear cells were treated with glyburide (100 mM) and/or
LPS (0.5 mg/ml). After 20 h, we evaluated cell surface expression
and release of HMGB1 by FACS analysis and western blot,
respectively. The results showed that glyburide induced a 50%
reduction in constitutive expression of HMGB1 on cell surface in
CB and PB (P,0.05) (Fig. 5A). In addition, the ABC-1 inhibitor
prevented the LPS effect at 20 h after treatment, partially
restoring the constitutive cell surface expression of HMGB1 that
resulted decreased as consequence of protein release induced by
LPS (P.0.05). Western blot analysis indicated that glyburide
blocked HMGB1 secretion induced by LPS in CB and PB cells
(Fig. 5B). No cytotoxic effect was observed at 24 h after treatment
with glyburide by MTT cytotoxicity assay. Altogether, these data
Figure 3. HMGB1 is present mostly in CB adherent cells.
Mononuclear cells isolated from human CB and PB have been cultured
in complete growth medium. After 14 days, two cell populations have
been identified: adherent and non-adherent cells. (A) The cell surface
expression of HMGB1 was determined in the two cell populations by
flow cytometry analysis. Data are shown as percentage of cells
expressing HMGB1 and values are mean 6 SD of eight experiments
from different donors. Statistical analysis compared non-adherent
versus adherent cells or CB versus PB (*P,0.05, **P,0.01 paired
Student’s t test). (B) The fluorescence histogram plots displays HMGB1
levels in non-adherent and adherent CB (solid line) and PB cells (dotted
line) and the percentage of HMGB1 positive cells is indicted in graphs.
Data reported is representative of eight different experiments.
doi:10.1371/journal.pone.0023766.g003
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of HMGB1 is regulated through alternative, non-classical routes,
as also confirmed by enhancing of its expression (2-folds over
control) after Brefeldin A treatment (data not shown). The
pharmacological modulation of HMGB1 expression was associat-
ed to different intracellular localization of HMGB1, as demon-
strated by immunofluorescence analysis of CB cells co-stained with
anti-HMGB1 (stained in green) and membrane-specific PKH26
red fluorescent dye (Fig. 5C). Confocal immunofluorescence
microscopy revealed that in untreated CB cells HMGB1 was
localized mainly under and on the apical membrane. Moreover,
HGMB1 staining was observed to be concentrated at areas of cell-
cell contact. In glyburide treatment HMGB1 became less
concentrated and more dispersed resulting in a faint fluorescence,
as quantified by FACS analysis. Moreover, the green fluorescence
was often punctuate, suggesting cytoplasmic compartmentalization
of the protein within vesicles. Twenty hours after stimulation with
LPS, HMGB1 displayed a similar pattern of distribution observed
after glyburide treatment, confirming the lower cellular expression
of HMGB1 in treated than untreated cells observed by FACS
analysis. Following the glyburide treatment, the modification of
HMGB1 distribution induced by LPS was partially prevented,
restoring a distribution of HMGB1 concentrated around the
perimeter.
HMGB1 is up-regulated by aminobisphosfonates
Since HMGB1 was expressed on cd T lymphocytes, we
evaluated whether aminonobisphosphonate compounds (ABs),
Pamidronate (PAM) and Zoledronate (ZOL), known to induce
activation and proliferation of cd T lymphocytes, were able to
trigger HMGB1 expression. After 14 days of cell culture in
presence of ABs (1 mg/ml), FACS analysis indicated that cell
surface expressed HMGB1 was upregulated by PAM and ZOL,
reaching 2.2- and 3.5-folds induction over control in CB and PB
cells, respectively, after ZOL treatment (Fig. 6A). Furthermore,
both compounds determined an evident expansion of HMGB1
positive cd T cells which were markedly increased by ZOL
treatment (10-folds over control) (Fig. 6B). This data was
completely in agreement with evaluation of HMGB1 secretion
by western blot analysis performed 14 days after treatment with
1 mg/ml ABs. Both ABs led to a significant induction of HMGB1
secretion into extracellular environment (Fig. 6C). As observed
with cell surface expression, ZOL triggered a stronger release of
HMGB1 by CB and PB cells than PAM treatment. Even if PAM
showed to have a lower effect on upregulation of HMGB1
expression than ZOL, its efficacy on HMGB1 release was
significantly increased compared to control. Finally, to demon-
strate that ABs-induced release of HMGB1 was not determined by
cell death, at 14 day of treatment we evaluated apoptosis/necrosis
by flow cytometry analysis after Annexin V/Propidium Iodide
staining. No significant change in Annexin V and Propidium
Iodide positive cells was observed in ABs treatment in comparison
to control.
HMGB1 mediates migration of monocytes
Extracellular HMGB1 acts as immune-stimulatory signal that
promotes recruitment of inflammatory cells, as monocytes and
dendritic cells, by signaling through RAGE [30]. As we observed
HMGB1 release after treatment with different stimuli, pre-
conditioned medium generated from the culture of CB or PB
cells after 14 days with IL-2 treatment, has been evaluated for its
effect on cell migration. After 4 h pre-conditioned medium
induced migration of CB or PB CD14
+ monocytes through
porous membrane. The phenomenon resulted inhibited by using
Figure 4. Different stimuli induce cell surface-expressed
HMGB-1 and its secretion into extracellular environment.
Various activation signals, such as proinflammatory stimuli (TNF-a or
IL-2 or IL-15) or that mimic infection (LPS, SEB or PMA) have been used
to influence the cell surface expression and active secretion of HMGB1.
CB and PB cells have been treated with proinflammatory mediators for
14 days and stimuli that mimic infection for 48 h. (A) Cell surface
expression of HMGB1 has been analyzed by FACS analysis, evaluating
the percentage of positive cells. In bar graph the values are shown as
ratio between treated and untreated cells expressing HMGB1 (fold
induction). The values are the mean 6 SD of four experiments from
different donors. (B) The culture medium of CB or PB cells, which have
been analyzed in (A) for surface HMGB1 expression, has been evaluated
for its secretion by western blot analysis. The levels of protein shown in
(B), quantified by densitometric analysis, has been expressed as
arbitrary units. Western blot are representative of three independent
experiments. (C) Untreated CB cells or treated with LPS for 48 h were
fixed, permeabilized and stained with anti-HMGB1 antibody (green
channel) and membrane-specific PKH26 red fluorescent dye. The
fluorescence has been analyzed by confocal microscopy (Leica TCS SP5).
doi:10.1371/journal.pone.0023766.g004
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antagonist [31], and anti-RAGE antibody (40 mg/ml) (Fig. 7).
Moreover, the percentage of migrated cells resulted lower in
presence of anti-RAGE than BoxA, indicating the presence of
additional factors that binds RAGE in pre-conditioned medium.
The HMGB1-mediated migration of monocytes has been further
confirmed by using recombinant HMGB1 protein that induced a
similar percentage of migrated cells as observed in pre-conditioned
medium in presence of anti-RAGE antibody (data not shown).
Finally, the secreted HMGB1 did not induce stem cells
chemotaxis, because lacking RAGE expression, which is present
Figure 5. HMGB1 expression is impaired by inhibitor of the Atp
binding cassette transporter ABC-1. To characterize the secretion
pathway of HMGB1, mononuclear cells were treated with 100 mM
glyburide, ABC-1 inhibitor, in presence or absence of LPS (0.5 mg/ml).
(A) After 20 h, cell surface-expressed HMGB1 was evaluated by FACS
analysis in CB and PB cells. The values are shown as ratio between
treated and untreated cells expressing HMGB1 (fold induction). The
values are the mean 6 SD of three experiments from different donors.
Statistical analysis compared treated versus untreated cells (*P,0.05
paired Student’s t test). (B) The culture medium of CB or PB cells, which
have been analyzed in (A), has been evaluated by western blot analysis
to detect its secretion. Western blot is representative of three
independent experiments. (C) CB cells were stained with anti-HMGB1
antibody (green channel) and membrane-specific PKH26 red fluores-
cent dye and analyzed by confocal mycroscopy. HMGB1 expression was
evaluated in untreated and glyburide treated CB cells (Top and bottom
left panel) or LPS and LPS plus glyburide treated CB cells (Top and
bottom right panel) after 20 h of activation.
doi:10.1371/journal.pone.0023766.g005
Figure 6. HMGB1 is up-regulated by Pamidronate and Zole-
dronate in CB and PB cells. Mononuclear cells isolated from CB and
PB have been treated with Pamidronate (1 mg/ml) and Zoledronate
(1 mg/ml). (A) After 14 days, cell surface expression of HMGB1 has been
analyzed by FACS analysis and the values, shown as fold induction, are
the product of ratio between treated and untreated cells expressing
HMGB1. (B) By multi-color flow cytometric analysis, CB and PB cells have
been gated for lymphocytes and stained with HMGB1, CD3 and
gammadelta (Vd2) antibodies. The ratio between treated and untreated
HMGB1
+CD3
+ cells is shown as fold induction. The values reported are
mean 6 SD of four experiments from different donors. (C) The secretion
of HMGB1 in cell culture medium was evaluated by western blot analysis.
Densitometric analysis of western blot has been expressed as arbitrary
units. Western blot is representative of three independent experiments.
doi:10.1371/journal.pone.0023766.g006
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inhibitory effect of anti-RAGE antibody on monocytes migration
(data not shown).
Discussion
High-mobility group box 1 has been isolated from calf thymus
as an abundant nuclear protein over 30 years ago [32]. Recent
studies demonstrated that HMGB1 is both actively secreted from
activated leukocytes, as a late cytokine mediator [31,33,34] and
passively released from necrotic or damaged cells [17]. Therefore,
the released HMGB1 acts as trigger of inflammation, attracting
inflammatory cells, and tissue repair in autocrine/paracrine
fashion.
The importance of HMGB1 as inflammatory mediator
examined in adult immune system has been also discovered in
fetuses and newborns in which soluble RAGE and HMGB1 are
active participants of the tissue injury process [27]. Moreover, in
neonates with asphyxia it has been suggested that the elevation of
HMGB1 might be associated with abnormal inflammatory
responses involving the excessive production of proinflammatory
cytokines [35]. The important role of HMGB1 in fetal immune
system has been corroborated by data demonstrating that in
response to stimuli HMGB1 secreted by human umbilical vein
endothelial cells (HUVEC)triggers inflammatory responsesthrough
up-regulation of adhesion molecules and release of soluble
proinflammatory mediators from endothelial cells [36,37]. Fetal
and newborn immune system is characterized to be phenotypically
and functionally immature [38]. The innate immune system is the
first line of defense against infections in neonates, providing critical
protection before the generation of an appropriate adaptive
immune response. In consideration of the essential role of neonatal
immune responses and the important biological function of
HMGB1 as bridge between innate and adaptative immune
responses, here we have shown for the first time that HMGB1 is
expressedandsecreted from mononuclear cells isolatedhuman cord
blood. By FACS analysis, we demonstrated that CB cell surface
membranes are positive to HMGB1 and its expression is
significantly higher in adherent cells than non-adherent cells
obtained after long term cell culture. These results show that
constitutive HMGB1 expression is confined to a population of
differentiated cells, likely myeloid DC precursors in CB and PB.
Conversely, lymphocytes, as CD4 or cd T cells, present a small cell
fraction positive for HMGB1. These findings are completely in
agreement with theroleofHMGB1 inregulatingimmune response,
in which activated monocytes and dendritic cells are the main
sourceofHMGB1release,promotingtheirfunctionalmaturationin
autocrine/paracrine fashion and sustaining the proliferation and
polarization of antigen-specific T-cells towards a Th1 phenotype
(CD4). cd T cells represent a small subset of T cells that possess a
distinct T cell receptor (TCR) on their surface [39]. These cells
exhibit several characteristics that place them, as HMGB1, at the
border between the more evolutionarily primitive innate immune
system and the adaptive immune system. Thus, our observations
give further evidence to the important role of HMGB1 in innate
immunityinwhichmacrophages/monocytes,DCand cdTcellsare
the main components. Vc9Vd2 T cells, which represent the major
subset of circulating human cd T cells, react against a set of non-
peptidic, phosphorilated antigens recognized in a TCR-dependent
manner [40]. These compounds derive from the mevalonate
pathway which is essential for mammalian cells in the sterol
synthesis, cell growth and membrane integrity. Other human cd T
cell antigens are synthetic compounds Aminobisphosphonate, such
as Pamidronate and Zoledronate [41],known as potent inhibitors of
osteoclast-mediated bone resorption used for the treatment of
osteoporosis, bone metastasis and cancer [21,42]. It has been shown
that bisphosphonates exert a stimulatory effect on adult peripheral
blood cd T cells, in vitro and in vivo, by inhibiting the mevalonate
pathway [43–45]. Recently, we have reported that the treatment
with ABs induces proliferative responses in cord blood Vd2 T cells
accompanied by modifications of their naı ¨ve phenotype towards a
regulatory subset, indicating that they are not inherently unrespon-
sive [46,47]. In this study, we demonstrated that PAM and ZOL
trigger cell surfaced expressed HMGB1 in CB and PB cells with an
evident increase of HMGB1 positive cd T cells. Furthermore, ABs
treatment leads to remarkable secretion of HMGB1 in extracellular
environments. This study provide the first demonstration that ABs
treatment modulate the expression of HMGB1 in CB cells,
involving Vd2 T-cells directly or throughout their presentation by
APC cells (monocyte lineage) which modulate surface molecules or
release cytokines needed for optimal Vd2 T cell activation, as
reported by Miyagawa F et al [48]. Moreover, the enhanced
secretion of HMGB1 is not caused by increased apoptosis or
necrosis, as demonstrated by FACS analysis. Different stimuli, and
not only ABs, are able to modulate HMGB1 expression in CB. In
our study, we demonstrated that stimuli that mimic infection (LPS,
SEB or PMA) or pro-inflammatory mediators, as TNF-a or IL-2 or
IL-15, induce the cell surface expression of HMGB1 and its
secretion at 48 h or 14 days after treatment, respectively. Besides,
the addition of glyburide, an ABC-1 inhibitor, inhibits LPS-induced
secretion, indicating that HMGB1 is released by non-classical
secretion pathway, as previously showed by Gardella S. et al [29].
Interestingly, the inhibition of HMGB1 secretion is strictly cor-
related to its cell surface expression, quantified by FACS analysis, in
which ABC-1 inhibitor is able to reduce either its constitutive or
inducible expression, demonstrating a role of cell membranes in
HMGB1 secretion. As confirmed by confocal microscopy analysis,
merged images of LPS treated CB cells verify the almost complete
colocalization of HMGB1 and plasma membrane. Moreover,
HGMB1 staining is often visualized punctuate, suggesting com-
partmentalization of the protein within cytoplasmic vesicles and is
predominantly localized toward the apical ends, areas of cell-cell
contact. Our data are in agreement with data presented by Beer
Figure 7. BoxA or anti-Rage antibody partially inhibits
monocytes migration. Fresh mononuclear cells isolated from CB
and PB have been added to upper well of transwell chamber to
measure cell migration induced by pre-conditioned medium generated
from the culture of CB or PB cells after 14 days of IL-2 treatment. The
migration of monocytes (CD14
+ cells) into lower chamber has been
evaluated by FACS analysis. Noninhibited migration was defined as
100%. Bars represent mean 6 SD of three different experiments. The
inhibition of monocytes migration has been obtained by adding BoxA
or anti-RAGE antibody in upper well of transwell chamber (***P,0.001).
doi:10.1371/journal.pone.0023766.g007
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that HMGB1 is actively secreted from cells by multivescicular
endosomes fuse with plasma membrane or that monocytes/
macrophages express at cell surface HMGB1, indicating HMGB1
as mediator of cell-to-cell or cell-to-matrix interaction to facilitate
their recruitment by binding RAGE at endothelial cells [50].
Results presented herein provide a new insight into the role of
HMGB1 in CB innate immune response. We demonstrate that
stimuli, as LPS or cytokines or synthetic compounds, can initiate a
cascade of events that lead to the activation of immune cells and
secretion of mediators, as HMGB1. Once secreted into extracel-
lular milieu, HMGB1 can function as a cytokine to contribute to
infectious and inflammatory disorders, as confirmed by our data of
its ability on CB monocytes recruitment, mediated by RAGE.
Human umbilical vein endothelial cells release HMGB1 and
express RAGE. Therefore, HMGB1, which is involved in a
paracrine interaction, might play a crucial role in transendothelial
migration and consequently in inflammatory immune response in CB.
Whereas a blockade of extracellular HMGB1 might represent a
suitable therapeutic target for the treatment of sepsis, the
development of the appropriate cell-mediated immunity, which is
associated with a Th1 type immune response, is essential for
successful immunization. Besides, extracellular HMGB1 has been
shown to act as immune adjuvant by enhancing immunogenicity of
apoptoticlymphomacellsand elicitingantibodyresponsestosoluble
ovalbumin protein [51]. Moreover, a short peptide, named Hp91,
identified within the B box domain of HMGB1, induced activation
of human and mouse DCs, increasing secretion of pro-inflamma-
tory cytokines and chemokines, including the Th1 cytokine, IL-12
[52].Therefore,theseimmunostimulatorypropertiesmakeHMGB1
an attractive candidate as an adjuvant for vaccine development. The
stimulation of neonatal response with vaccines has certain medical
advantages and, namely, produce early protection for the vulnerable
newbornperiod.Successfulvaccinescontainanadjuvantcomponent
that activates the innate immune system, thereby eliciting antigen-
specific immune responses. Many adjuvants appear to be ligands for
toll-like receptors (TLR), as HMGB1, which are promising targets
for the development of novel adjuvants to elicit vaccine immuno-
genicity [53,54]. In this scenario, aminobishoshponates that are
able to stimulate innate immunity, as cd T cells in CB [47], and to
induce HMGB1 secretion may be an immuno-modulating tool to
approach neonatal pathologies. Moreover, in adult counterpart,
considering that ZOL or PAM exert also anti-cancer activity by
inducing apoptosis, ABs, as other anticancer agents, may interfere
in the complex interaction between tumor and host immune
system by the release of inflammatory mediators, such as HMGB1,
which mediate cross-presentation of tumor antigens via binding on
TLR4 and the promotion of tumor specific cytotoxic T cell
responses [55,56]. In conclusion, by modulating the activity of
HMGB1 we might provide a potential therapeutic target in adult
and neonatal pathologies.
Materials and Methods
Ethics statement
Human umbilical cord blood and buffy coats from peripheral
blood donations samples were collected after obtaining informed
consent. The consent was written and approved from all
participants. All blood samples were only collected from donors
that had consented scientific use of blood products. Ethics
Committee approval for this study is not required according to
institutional guidelines. In particular, approval from the Ethics
Committee of our institution was not necessary because blood
samples were obtained in compliance with Italian legislation and
donors gave informed written consent to donation for research
purpose in case of sample with cell content numerically unsuited
for clinical use, and therefore are considered as residual sample or
waste material. Informed written consent has been requested to
the donors or to the authorized parents.
Preparation of cells and culture conditions
Cord blood (CB) was obtained from healthy mothers according
to institutional guidelines. Anonymous buffy coats from peripheral
blood (PB) donations were collected from healthy blood bank
donors. CB samples were obtained from spontaneous partum and
normal full-term pregnancies by venipuncture of umbilical vein
immediately after delivery. Samples were collected at S. Pietro
Fatebenefratelli hospital in Rome. Cord blood was diluted (1:1)
with phosphate-buffered saline, PBS (Dulbecco’s Phosphate Buffer
Saline), and further diluted (1:1) with a solution of 4% dextran in
PBS (Sigma Aldrich, St Louis, USA). After sedimentation of
erythrocytes, CB and PB samples was layered over Ficoll-Hypaque
(Sigma-Aldrich, St. Louis, USA) density gradient and centrifu-
gated at 1,800 rpm for 20 minutes. Freshly isolated mononuclear
cells of CB and PB were cultured at 3610
6/ml in RPMI 1640
(Sigma Aldrich) supplemented with 10% FBS (Sigma Aldrich),
2 mM L-glutamine (Sigma Aldrich), 10 UI/ml penicillin-strepto-
mycin (Sigma Aldrich).
HeLa cells (ATCC CCL-2) human cervical carcinoma, were
cultures in DMEM (Sigma Aldrich) supplemented with 10% FBS
(Sigma Aldrich), 2 mM L-glutamine (Sigma Aldrich), 10 UI/ml
penicillin-streptomycin (Sigma Aldrich).
Cell treatment
Fresh CB and PB cells were treated with the following stimuli:
IL-2 (20 ng/ml) (Roche), TNF-a (20 ng/ml) (eBioscience, Inc), IL-
12 (20 ng/ml) (eBioscience, Inc) or aminobisphosphonates,
Pamidronate and Zoledronate (Zometa, Novartis Pharmaceutical)
(1 mg/ml) for 14 days; Lipopolysaccharide (LPS) (500 ng/ml)
(Sigma Aldrich), Staphylococcus aureus Enterotoxin B (SEB)
(1 mg/ml) (Sigma Aldrich) or Phorbol 12-myristate 13-acetate
(PMA) (30 ng/ml) (Sigma Aldrich) for 48 h. Untreated mononu-
clear cells have been cultured in complete growth medium for
48 h and 14 days. For secreted HMGB1 detection, culture
supernatants were microcentrifuged at 12006g for 5 minutes and
frozen at 270uC until analysis.
Flow Cytometric Analysis of Surface-Expressed HMGB-1
and Expression of cellular differentiation markers
Surface expressed HMGB1 has been analyzed by flow
cytometry (FACSCalibur Flow Cytometry System, BD BioScienc-
es Pharmingen) using the anti rabbit-HMGB1 antibody (Sigma
Aldrich) and secondary FITC-conjugated antibody (BD Biosci-
ences) or Alexafluor 647–conjugated antibody (Molecular Probes,
Invitrogen). The surface expression of cell differentiation markers
have been evaluated with the following fluorescently-conjugated
antibodies: PE anti-human CD14 (M5E2), PE-Cy5 anti-human
CD11c (B-ly6), PE-Cy7 anti-human CD16 (3G8), PE anti-human
Vd2 (B6), PE anti-human CD8 (SK1), FITC anti-human CD4
(RPA-T4) (BD Biosciences, PharMingen) and APC anti-humam
CD3 (UCHT1) (eBioscience, Inc). The fluorescence labelling has
been performed by incubating cells at 4uC (protected from light) in
PBS with 4% bovine serum albumin for 30 minutes with
antibodies. Cells were subsequently washed, resuspended in
500 ml PBS and acquired on flow cytometer (FACSCalibur, BD
Biosciences). 100000 events have been collected and analyzed by
Cell Quest program (BD Biosciences).
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fixed and permeabilzed with Cytofix/Cytoperm solution (BD
Cytofix/Cytoperm Kit, BD BioSciences Pharmingen) prior to the
addition of anti-HMGB1 antibody.
Western Blot Analysis of Secreted HMGB1
CB and PB cell culture supernatants or complete culture
medium (100 ml) were boiled in reducing Laemmli sample buffer,
resolved on 12% SDS/PAGE under reducing conditions and
electrotransferred onto PVDF filters (Hybond-P, Amersham
Pharmacia Biotech, Milan, Italy), which were stained with
Ponceau S (Sigma) and de-stained prior to blocking with 5%
non-fat dry milk in PBS containing 0.05% Tween (Sigma) for 1 h.
Filters were stained with polyclonal rabbit anti-HMGB1 antibody
overnight at 4uC followed by anti-rabbit IgG horse-radish-
peroxidase-(HRP-) conjugated secondary antibody for 1 hour at
room temperature. HMGB1 detection was performed using Super
Signal substrate (Pierce, Rockford, IL) according to the manufac-
turer’s instructions. Quantitative evaluation of HMGB1 protein
was determined by densitometric analysis.
Inhibition of HMGB1 expression and secretion by ABC-1
inhibitor glyburide
In order to characterized the secretion pathway of HMGB1, CB
and PB mononuclear cells (3610
6 cells/ml) have been activated
with LPS (500 ng/mL) in presence of 100 mM glyburide (Sigma), a
potent inhibitor of the secretion via Atp binding cassette
transporter (ABC-1). After 20 hours HMGB1 has been evaluated
as cell surface expression and its secretion in the culture medium
by FACS and western blot analysis, respectively, as indicated
before. The potential cell toxic effects of glyburide and its solvent
(dymethylsulfoxide, DMSO) were determined by MTT.
Confocal fluorescence microscopy
CB and PB mononuclear cells (3610
6 cells/ml) have been
deposited on glass slides by centrifugation at 400 rpm for
5 minutes using a cytospin system (Thermo Shandon, Pittsburgh,
PA). They were air dried, fixed in cold 4% paraformaldehyde for
15 minutes. Cells were washed in PBS and permeabilized in 0.2%
Triton X-100 in PBS for 10 min at 4uC and then blocked with 1%
bovine serum albumin in PBS for 40 min. Immunofluorescence
staining of cells was performed using rabbit anti-HMGB1 antibody
(1:300) and anti-rabbit-FITC conjugated secondary antibody
(1:200). Antibodies dilutions in PBS containing 0.1%BSA were
added to cells and incubated for 1 h at room temperature. After
washing in PBS, general cell membrane labeling PKH26-GL red
fluorescent dye (1:250 dilution; Sigma) was added for 10 min at
room temperature. Cells were washed three times in PBS,
mounted using ProLong Gold antifade reagent (Molecular Probes,
Invitrogen) and then analyzed using confocal microscope (Leica
TCS SP5). Software: LAS AF version 1.6.3 (Leica Microsystem).
MTT assay
Cytotoxicity has been quantified by measurement of the
reduction of MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5- diphenylte-
trazolium bromide, a tetrazole) (Promega) to produce a dark blue
formazan product. MTT has been added to each well 20 h after
the beginning of the insult. After 3 h incubation, the Solubiliza-
tion/Stop Solution has been added to the culture wells to
solubilize the formazan product, and the absorbance at 570 nm
recorded using a 96-well plate reader (Bio-RadH Laboratories)
Detection of apoptosis
CBand PBmononuclearcells (1610
6 cells/mL)were washedwith
ice-coldPBSandthecellpelletswereresuspendedinice-coldbinding
buffer. Five mL Annexin V FITC solution and 5 mL propidium
iodide (Bender MedSystems, Austria) were added to 490 mLo ft h e
prepared cell suspension and incubated at 4uCf o r1 0m i ni nt h e
dark. Aliquots were directly aspirated into a FACSCalibur flow
cytometer and apoptosis analysed by CellQuest program.
Monocytes chemotaxis assay
Fresh mononuclear cells isolated from CB or PB were placed to
upper compartment of the Transwell chamber (3-mm pore size)
and pre–conditioned medium, generated from the culture of CB
or PB cells after 14 days of treatment and centrifugation at
12006g, was added in lower well. After 4 h, migrated cells were
characterized by FACS analysis. BoxA (HMGBiotech, Milan,
Italy) or anti-RAGE antibody (Millipore, USA) were used to
inhibit HMGB1 mediated cell migration.
Statistical Analysis
Student’s t-test (one-tail) has been used to assess the significance
of differences in HMGB1 expression. Differences were considered
significant if the probability of the null hypothesis was less than five
percent (* P,0.05, ** P,0.01, *** P,0.001).
Supporting Information
Figure S1 Adherent cells are myeloid DC precursors
expressing HMGB1. At 14 days after isolation from CB and
PB, adherent mononuclear cells were characterized by multi-color
flow cytometric analysis of surface-expressed HMGB1 and
expression of cellular differentiation markers. CD14
+CD11c
+
and CD14
2 CD11c
+ phenotypes are adherent cells expressing
HMGB1. Values (mean 6 SD of five experiments from different
donors) are expressed as percentage of HMGB1 positive cell subset
among the totality of HMGB1 expressing cells.
(TIF)
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